Andrew Tolve writes that patient groups are yet another means to provide the education and support needed to boost adherance. The full article is reported by Eye for Pharma on 9 Mar 2010.
Non-adherence is a serious financial concern. John Hosken of Eye for Pharma estimates that
“…drug companies are losing around 25 billlion euros each year simply through patients not taking their medicine.”
With such high stakes, patient groups could be an asset to industry’s toolbox.
(Source: Report from Patient Compliance Europe Conference, hosted by Eye for Pharma in 2006)